Novocure Ltd Ord Sh (NVCR) Stock Price, Quote & News

Company Profile

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, p...

Industry: Medical Devices

Sector: Healthcare

Website: www.novocure.com

Address:

Neuhofstrasse 21, Baar, Switzerland

Tdorsey1776 May. 13 at 2:24 PM

$NVCR Not enough sell pressure to knock this down, looks like it will continue to grind higher as the shorts cover and perhaps we are seeing some new buying. Risk/reward still strong IMO. GLTA

1 · Reply

CCrazy1990 May. 12 at 9:32 PM

$NVCR now FDA Commissioner pushed out. What an absolute cluster F DHHS and its “leader” are. This is what happens when you hire lackeys over competent people for critical positions like Sec of DHHS.

1 · Reply

CCrazy1990 May. 12 at 8:41 PM

$NVCR shares short went from 8.71M on April 16 to 6.97M on April 30 (the day Q1 earnings release dropped)

0 · Reply

Stonkapedia May. 12 at 8:20 PM

$NVCR awww look at this POS go 💩

0 · Reply

Tdorsey1776 May. 12 at 5:15 PM

$NVCR https://seekingalpha.com/article/4859323-why-novocure-is-failing-to-disrupt-nsclc

0 · Reply

Tdorsey1776 May. 12 at 5:13 PM

$NVCR Shorts and naysayers...don't let the door hit you in the azzzzzz on the way out

1 · Reply

Tdorsey1776 May. 11 at 2:27 PM

$VRDN $NVCR

2 · Reply

Tdorsey1776 May. 11 at 1:40 PM

$NVCR Shorts still trying to sneak out the back door.....

2 · Reply

scotofool May. 11 at 10:13 AM

$NVCR mates dungeondwellas show smileys.Yet wanker ceo lyes no userdoccies panky fakky datas. $NVCR proper trash, target 7

1 · Reply

GordonGecko_was_THE_MAN May. 9 at 12:09 AM

$NVCR filing after the close. Apparently, Soleus Capital has been buying. In Q1'26, appears that Soleus added almost 2M shares. Now owns 10.49M shares, or 9.1%.

5 · Reply

Novocure price target raised to $17 from $13.50 at Wells Fargo

2026-05-01T12:15:56.000Z - 12 days ago

Novocure price target raised to $20 from $16 at Evercore ISI

2026-04-30T13:13:37.000Z - 13 days ago

Novocure reports Q1 EPS (62c), consensus (51c)

2026-04-30T13:12:44.000Z - 13 days ago

Novocure raises FY26 revenue view to $690M-$710M from $675M-$705M

Apr 30, 2026, 8:00 AM EDT - 13 days ago

NovoCure Earnings Call Transcript: Q1 2026

Apr 30, 2026, 7:00 AM EDT - 13 days ago

Novocure Reports First Quarter 2026 Financial Results

2026-04-06T12:12:23.000Z - 5 weeks ago

Novocure price target lowered to $16 from $23 at Evercore ISI

Apr 1, 2026, 7:00 AM EDT - 6 weeks ago

Novocure to Report First Quarter 2026 Financial Results

2026-03-26T11:11:40.000Z - 6 weeks ago

Novocure announces results from Phase 2 PANOVA-4 trial met primary endpoint

Mar 26, 2026, 7:00 AM EDT - 6 weeks ago

Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer

Mar 10, 2026, 11:20 AM EDT - 2 months ago

NovoCure Transcript: Leerink Global Healthcare Conference 2026

2026-03-02T12:33:53.000Z - 2 months ago

Novocure gets reimbursement approval in Japan for Optune Lua

2026-03-02T12:30:14.000Z - 2 months ago

Novocure gets reimbursement approval in Japan for Optune Lua

Mar 2, 2026, 7:00 AM EST - 2 months ago

Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer

Feb 27, 2026, 4:30 PM EST - 2 months ago

Novocure to Participate in 2026 Leerink Global Healthcare Conference

Feb 26, 2026, 8:00 AM EST - 2 months ago

NovoCure Earnings Call Transcript: Q4 2025

2026-02-26T12:36:11.000Z - 2 months ago

Novocure reports Q4 EPS (22c), consensus (41c)

2026-02-26T12:35:04.000Z - 2 months ago

Novocure sees FY26 revenue $675M-$705M, consensus $681.24M

Feb 26, 2026, 7:00 AM EST - 2 months ago

Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update

2026-02-25T14:00:43.000Z - 2 months ago

Novocure says CMS rescinds revocation of billing privileges

2026-02-25T13:59:52.000Z - 2 months ago

Novocure jumps 11% after CMS reinstates Medicare billing privileges

Feb 24, 2026, 7:00 AM EST - 2 months ago

Tumor Treating Fields (TTFields) Therapy to be Covered for Patients with Newly Diagnosed Glioblastoma Through British Columbia Cancer (BC Cancer)

2026-02-12T14:40:28.000Z - 3 months ago

Unusually active option classes on open February 12th

BP CROX FDX LVS MU SGHC TZA

2026-02-12T13:09:04.000Z - 3 months ago

Why Is NovoCure Stock (NVCR) Up Today?

Feb 12, 2026, 6:53 AM EST - 3 months ago

This Biotech Stock Is Jumping 25% After Getting an FDA Boost

Feb 12, 2026, 6:15 AM EST - 3 months ago

What's Happening With NovoCure Stock?

2026-02-12T11:05:11.000Z - 3 months ago

Novocure price target raised to $47 from $39 at H.C. Wainwright

Feb 11, 2026, 6:33 PM EST - 3 months ago

Novocure Gets FDA Approval for Pancreatic Cancer Treatment; Shares Soar

2026-02-11T23:00:22.000Z - 3 months ago

Novocure’s Optune Pax approved by FDA to treat pancreatic cancer

Feb 11, 2026, 5:54 PM EST - 3 months ago

U.S. FDA Approves Novocure's Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer

Jan 14, 2026, 12:45 PM EST - 4 months ago

NovoCure Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 7:00 AM EST - 4 months ago

Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update

Dec 22, 2025, 7:00 AM EST - 5 months ago

Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference

Dec 2, 2025, 11:30 AM EST - 5 months ago

NovoCure Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 1, 2025, 7:00 AM EST - 5 months ago

Novocure Appoints Company President Frank Leonard as Chief Executive Officer

Nov 26, 2025, 7:00 AM EST - 6 months ago

Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference

Nov 19, 2025, 9:00 AM EST - 6 months ago

NovoCure Transcript: Jefferies London Healthcare Conference 2025

Nov 12, 2025, 7:00 AM EST - 6 months ago

Novocure to Participate in 2025 Jefferies Global Healthcare Conference

Oct 30, 2025, 8:00 AM EDT - 6 months ago

NovoCure Earnings Call Transcript: Q3 2025

Oct 30, 2025, 7:00 AM EDT - 6 months ago

Novocure Reports Third Quarter 2025 Financial Results

Oct 15, 2025, 7:00 AM EDT - 7 months ago

Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress

Oct 1, 2025, 7:00 AM EDT - 8 months ago

Novocure to Report Third Quarter 2025 Financial Results

Sep 29, 2025, 4:30 PM EDT - 8 months ago

Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting

Sep 15, 2025, 7:00 AM EDT - 8 months ago

Novocure's Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC)

Sep 10, 2025, 3:20 PM EDT - 8 months ago

NovoCure Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 9, 2025, 2:00 PM EDT - 8 months ago

NovoCure Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 9:30 AM EDT - 8 months ago

NovoCure Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Aug 28, 2025, 7:00 AM EDT - 9 months ago

Novocure Announces Upcoming Investor Events

Aug 25, 2025, 7:00 AM EDT - 9 months ago

Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain

Aug 20, 2025, 7:00 AM EDT - 9 months ago

Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer

Jul 24, 2025, 8:00 AM EDT - 10 months ago

NovoCure Earnings Call Transcript: Q2 2025

Jul 24, 2025, 7:00 AM EDT - 10 months ago

Novocure Reports Second Quarter 2025 Financial Results

Jul 1, 2025, 7:00 AM EDT - 11 months ago

Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025

Jun 30, 2025, 7:00 AM EDT - 11 months ago

Novocure to Report Second Quarter 2025 Financial Results

Jun 4, 2025, 12:50 PM EDT - 1 year ago

NovoCure Transcript: Jefferies Global Healthcare Conference 2025

May 31, 2025, 8:01 PM EDT - 1 year ago

NovoCure Transcript: Study Result

May 31, 2025, 3:08 PM EDT - 1 year ago

Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

ZLAB

May 31, 2025, 8:00 AM EDT - 1 year ago

Results From the Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

Apr 24, 2025, 8:00 AM EDT - 1 year ago

NovoCure Earnings Call Transcript: Q1 2025

Apr 24, 2025, 7:00 AM EDT - 1 year ago

Novocure Reports First Quarter 2025 Financial Results

Apr 23, 2025, 10:16 AM EDT - 1 year ago

Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual Meeting

Apr 22, 2025, 7:09 AM EDT - 1 year ago

Novocure's Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer

Apr 1, 2025, 7:00 AM EDT - 1 year ago

Novocure to Report First Quarter 2025 Financial Results

Mar 11, 2025, 4:20 PM EDT - 1 year ago

NovoCure Transcript: Leerink’s Global Healthcare Conference 2025

Mar 4, 2025, 7:00 AM EST - 1 year ago

Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference

Feb 27, 2025, 8:00 AM EST - 1 year ago

NovoCure Earnings Call Transcript: Q4 2024

Feb 27, 2025, 7:00 AM EST - 1 year ago

Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

Jan 22, 2025, 4:00 AM EST - 1 year ago

Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland

Jan 15, 2025, 12:00 PM EST - 1 year ago

NovoCure Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 13, 2025, 7:00 AM EST - 1 year ago

Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update

Jan 3, 2025, 7:00 AM EST - 1 year ago

Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference

Dec 5, 2024, 12:00 PM EST - 1 year ago

NovoCure Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 4, 2024, 2:10 PM EST - 1 year ago

NovoCure Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Dec 2, 2024, 7:17 AM EST - 1 year ago

Novocure's pancreatic cancer treatment meets main goal in late-stage study

Dec 2, 2024, 7:02 AM EST - 1 year ago

Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

ZLAB

Dec 2, 2024, 7:00 AM EST - 1 year ago

Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

Nov 27, 2024, 7:00 AM EST - 1 year ago

Novocure to Participate in Upcoming Investor Conferences

Nov 21, 2024, 7:05 AM EST - 1 year ago

Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma

Nov 21, 2024, 7:00 AM EST - 1 year ago

FDA Approves Novocure's Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma

Oct 30, 2024, 8:00 AM EDT - 1 year ago

NovoCure Earnings Call Transcript: Q3 2024

Oct 30, 2024, 7:02 AM EDT - 1 year ago

Novocure Appoints Christoph Brackmann as Chief Financial Officer

Oct 30, 2024, 7:00 AM EDT - 1 year ago

Novocure Reports Third Quarter 2024 Financial Results

Oct 15, 2024, 4:43 PM EDT - 1 year ago

FDA Approves Novocure's Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer

Oct 1, 2024, 7:00 AM EDT - 1 year ago

Novocure to Report Third Quarter 2024 Financial Results

Sep 9, 2024, 7:00 AM EDT - 1 year ago

Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy

Sep 4, 2024, 4:30 PM EDT - 1 year ago

NovoCure Transcript: 2024 Wells Fargo Healthcare Conference

Sep 3, 2024, 7:00 AM EDT - 1 year ago

Novocure Announces Planned CEO Transition

Tdorsey1776 May. 13 at 2:24 PM

$NVCR Not enough sell pressure to knock this down, looks like it will continue to grind higher as the shorts cover and perhaps we are seeing some new buying. Risk/reward still strong IMO. GLTA

1 · Reply

CCrazy1990 May. 12 at 9:32 PM

1 · Reply

CCrazy1990 May. 12 at 8:41 PM

$NVCR shares short went from 8.71M on April 16 to 6.97M on April 30 (the day Q1 earnings release dropped)

0 · Reply

Stonkapedia May. 12 at 8:20 PM

$NVCR awww look at this POS go 💩

0 · Reply

Tdorsey1776 May. 12 at 5:15 PM

$NVCR https://seekingalpha.com/article/4859323-why-novocure-is-failing-to-disrupt-nsclc

0 · Reply

Tdorsey1776 May. 12 at 5:13 PM

$NVCR Shorts and naysayers...don't let the door hit you in the azzzzzz on the way out

1 · Reply

Tdorsey1776 May. 11 at 2:27 PM

$VRDN $NVCR

2 · Reply

Tdorsey1776 May. 11 at 1:40 PM

$NVCR Shorts still trying to sneak out the back door.....

2 · Reply

scotofool May. 11 at 10:13 AM

$NVCR mates dungeondwellas show smileys.Yet wanker ceo lyes no userdoccies panky fakky datas. $NVCR proper trash, target 7

1 · Reply

GordonGecko_was_THE_MAN May. 9 at 12:09 AM

$NVCR filing after the close. Apparently, Soleus Capital has been buying. In Q1'26, appears that Soleus added almost 2M shares. Now owns 10.49M shares, or 9.1%.

5 · Reply

BB_88_ May. 8 at 11:33 PM

$S $NVCR had these both at all time lows fml didn’t hold

0 · Reply

CCrazy1990 May. 8 at 8:06 PM

$NVCR another good week. See you fellow degenerates on Monday!

0 · Reply

BB_88_ May. 8 at 6:38 PM

$NVCR covered

0 · Reply

BB_88_ May. 8 at 6:26 PM

$NVCR as expected crack

0 · Reply

BB_88_ May. 8 at 6:01 PM

$NVCR here is the crack back to 16. Listen I’m bullish I had buys at 9 and 10 never held :(

0 · Reply

BB_88_ May. 8 at 5:56 PM

$NVCR think she consolidating before crack. What happens first cross 17.9 or drop below 17.7

0 · Reply

Tdorsey1776 May. 8 at 5:43 PM

$NVCR Here you go Gecko.....

2 · Reply

BB_88_ May. 8 at 5:37 PM

$NVCR 17.5 crack soon

0 · Reply

BB_88_ May. 8 at 5:29 PM

$NVCR likes to spike and fade calling fade in to close

0 · Reply

BB_88_ May. 8 at 5:14 PM

$NVCR short 1400 in to close

1 · Reply

CCrazy1990 May. 8 at 4:19 PM

$NVCR welfare check on you. You good? 👀 . Ouch…pain.

1 · Reply

Tdorsey1776 May. 8 at 3:24 PM

$NVCR The position adjustment in response to Panc is not Lung 2.0 continues..... short covering along with net longs, nice grind higher. GLTA

2 · Reply

Market Cap	2.10B
Revenue (ttm)	655.35M
Net Income (ttm)	-136.23M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-20.79%
Debt to Equity Ratio	0.71

Volume	1,064,821
Avg Vol	1,511,818
Day's Range	N/A - N/A
Shares Out	115.82M
Stochastic %K	89%
Beta	0.90
Analysts	Strong Sell
Price Target	$26.00